Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06533228 · ClinicalTrials.gov registry record

Helmsley 3.0: Abbreviated MRE

A clinical trial of Crohn's Disease, sponsored by Children's Hospital Medical Center, Cincinnati.

Recruiting
Registry status
300
Enrollment target
2
Study locations

NCT06533228: Recruiting study of Crohn's Disease, sponsored by Children's Hospital Medical Center, Cincinnati.

NCT06533228 is a study of Crohn's Disease that is actively recruiting participants, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 300 participants, below the 2,392-participant average among 105 other Crohn's Disease trials with a reported enrollment target (87% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06533228, a study of Crohn's Disease, is actively recruiting participants, sponsored by Children's Hospital Medical Center, Cincinnati.

RECRUITING
Registry status
300 participants
Enrollment target
2
Study locations

Study Summary

The purpose of our study is to compare an abbreviated magnetic resonance imaging (MRI) of the bowel or magnetic resonance enterography (MRE) protocol to a conventional, standard of care MRE in children and adults with Crohn's Disease.

Primary Outcome

Our abbreviated magnetic resonance enterography (MRE) will be non-inferior to a standard clinical MRE in detecting small bowel inflammation, strictures and penetrating disease associated with Crohn's Disease.

Conditions Studied

Interventions

  • DIAGNOSTIC_TEST Magnetic Resonance Imaging (MRI) or Magnetic Resonance Enterography (MRE)

Study Locations (2)

Minnesota

  • Mayo Clinic - Rochester

New York

  • NYU Langone - New York

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2024-09-01
Est. Completion 2028-02

What NCT06533228 shows while recruiting

NCT06533228 is an observational study that tracks outcomes without assigning an intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 2,392-participant average among 105 other Crohn's Disease trials with a reported enrollment target (87% lower).

The record links to 1 condition, with Crohn's Disease appearing as the primary indexed condition, and to 1 intervention - of which Magnetic Resonance Imaging (MRI) or Magnetic Resonance Enterography (MRE) is the first listed.

NCT06533228 reports a single indexed study location in Minnesota, New York.

Frequently Asked Questions

What is clinical trial NCT06533228 about?

NCT06533228 is a clinical study titled "Helmsley 3.0: Abbreviated MRE". The purpose of our study is to compare an abbreviated magnetic resonance imaging (MRI) of the bowel or magnetic resonance enterography (MRE) protocol to a conventional, standard of care MRE in children and adults with Crohn's Disease.

What is the current status of trial NCT06533228?

This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2024-09-01. Estimated completion is 2028-02.

What conditions does trial NCT06533228 study?

This clinical trial studies the following conditions: Crohn's Disease.

What interventions are being tested in trial NCT06533228?

The interventions under investigation include: Magnetic Resonance Imaging (MRI) or Magnetic Resonance Enterography (MRE) (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT06533228?

This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06533228 being conducted?

This trial has 2 study locations across Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Crohn's Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06533228's enrollment target sits among peer trials

300 37th of 105 higher than 66 of 105 other Crohn's Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Crohn's Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00353483 · 300 participants

    Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells

  • NCT00588185 · 300 participants · NA

    [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer

  • NCT00682032 · 300 participants · NA

    The Effect of Beta-glucan in Non-Small Cell Lung Cancer

  • NCT00870064 · 300 participants · NA

    The Treatment of Type I Open Fractures in Pediatrics

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06533228, the US trial registry maintained by the National Library of Medicine. NCT06533228 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.